A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.

PubWeight™: 2.63‹?› | Rank: Top 1%

🔗 View Article (PMID 23466307)

Published in J Hepatol on March 04, 2013

Authors

Bruno Sangro1, Carlos Gomez-Martin, Manuel de la Mata, Mercedes Iñarrairaegui, Elena Garralda, Pilar Barrera, Jose Ignacio Riezu-Boj, Esther Larrea, Carlos Alfaro, Pablo Sarobe, Juan José Lasarte, Jose L Pérez-Gracia, Ignacio Melero, Jesús Prieto

Author Affiliations

1: Liver Unit and HPB Oncology, Clinica Universidad de Navarra, Pamplona, Spain. bsangro@unav.es

Associated clinical trials:

Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma | NCT01008358

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) | NCT02821754

Articles citing this

Retracted The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies. Biomed Res Int (2015) 1.40

Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol (2015) 1.33

Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology (2014) 1.16

T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. Cell Death Dis (2015) 1.09

Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2015) 1.06

New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci (2015) 1.02

Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review. World J Hepatol (2015) 1.01

Hepatocellular carcinoma from an immunologic perspective. Clin Cancer Res (2013) 1.00

Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma. Immunotherapy (2016) 0.96

Hepatocellular carcinoma: Where there is unmet need. Mol Oncol (2015) 0.93

Functional and genetic deconstruction of the cellular origin in liver cancer. Nat Rev Cancer (2015) 0.92

Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy. Acta Pharmacol Sin (2015) 0.92

Hyper-IL-15 suppresses metastatic and autochthonous liver cancer by promoting tumour-specific CD8+ T cell responses. J Hepatol (2014) 0.90

Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC. Cancer Immunol Res (2016) 0.90

Liver immunology and its role in inflammation and homeostasis. Cell Mol Immunol (2016) 0.88

Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. Oncotarget (2016) 0.88

Immunotherapy for hepatocellular carcinoma: From basic research to clinical use. World J Hepatol (2015) 0.88

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. J Crohns Colitis (2016) 0.84

Immune-based Therapy Clinical Trials in Hepatocellular Carcinoma. J Clin Cell Immunol (2015) 0.84

Progress in systemic therapy of advanced hepatocellular carcinoma. World J Gastroenterol (2016) 0.83

Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma. Cancer Res Treat (2016) 0.83

Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016. World J Gastroenterol (2016) 0.83

Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora? Semin Immunopathol (2017) 0.82

Induction of Multiple Immune Regulatory Pathways with Differential Impact in HCV/HIV Coinfection. Front Immunol (2014) 0.82

Clinical Development of Immune Checkpoint Inhibitors. Biomed Res Int (2015) 0.82

Facing the dawn of immunotherapy for hepatocellular carcinoma. J Hepatol (2013) 0.81

Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol (2016) 0.81

3β-hydroxysterol δ24-reductase on the surface of hepatitis C virus-related hepatocellular carcinoma cells can be a target for molecular targeting therapy. PLoS One (2015) 0.80

Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection. Mol Ther Methods Clin Dev (2015) 0.80

Restoring homeostasis of CD4(+) T cells in hepatitis-B-virus-related liver fibrosis. World J Gastroenterol (2015) 0.79

Current status and perspectives of immune-based therapies for hepatocellular carcinoma. World J Gastroenterol (2016) 0.79

Systemic therapy for advanced hepatocellular carcinoma: an update. J Gastrointest Oncol (2017) 0.79

T cell exhaustion: from pathophysiological basics to tumor immunotherapy. Cell Commun Signal (2017) 0.78

Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events. Oncologist (2016) 0.78

A Potential Inhibitory Profile of Liver CD68+ Cells during HCV Infection as Observed by an Increased CD80 and PD-L1 but Not CD86 Expression. PLoS One (2016) 0.78

Tremelimumab: research and clinical development. Onco Targets Ther (2016) 0.78

Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees. World J Hepatol (2015) 0.78

Prospect of the use of checkpoint inhibitors in hepatocellular cancer treatments. Cancer Manag Res (2017) 0.78

Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. World J Gastroenterol (2016) 0.78

Combinations of immunostimulatory antibodies with synergistic effects against spontaneous cancer. Oncoimmunology (2014) 0.77

Immune Checkpoint Blockade in Hepatocellular Carcinoma. Liver Cancer (2015) 0.77

Cases of spontaneous tumor regression in hepatobiliary cancers: implications for immunotherapy? J Gastrointest Cancer (2015) 0.77

Potentiality of immunotherapy against hepatocellular carcinoma. World J Gastroenterol (2015) 0.77

Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int (2017) 0.77

GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells ex vivo. Oncoimmunology (2015) 0.76

Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma. J Immunother Cancer (2015) 0.76

Clinical implications of basic research in hepatocellular carcinoma. J Hepatol (2015) 0.76

Immunobiology of hepatocarcinogenesis: Ways to go or almost there? World J Gastrointest Pathophysiol (2016) 0.76

Hepatocellular carcinoma: Will novel targeted drugs really impact the next future? World J Gastroenterol (2016) 0.76

Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series. J Immunother Cancer (2014) 0.76

Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy. Oncotarget (2017) 0.75

Tumor regulation of the tissue environment in the liver. Pharmacol Ther (2017) 0.75

Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update. Liver Cancer (2016) 0.75

Immune-Mediated Therapies for Liver Cancer. Genes (Basel) (2017) 0.75

Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial. Ann Oncol (2016) 0.75

Identification of a FOXP3(+)CD3(+)CD56(+) population with immunosuppressive function in cancer tissues of human hepatocellular carcinoma. Sci Rep (2015) 0.75

Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress. J Hematol Oncol (2017) 0.75

Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients. J Immunol Res (2015) 0.75

State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization. J Immunol Res (2016) 0.75

The Use of Genetic Alterations in the Development of Liver Cancer Drugs. Gastroenterol Hepatol (N Y) (2015) 0.75

Systematic evaluation of immune regulation and modulation. J Immunother Cancer (2017) 0.75

Immunotherapy in human colorectal cancer: Challenges and prospective. World J Gastroenterol (2016) 0.75

Advances in immunotherapy for the treatment of glioblastoma. J Neurooncol (2016) 0.75

Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma. J Hepatocell Carcinoma (2016) 0.75

Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future. Diseases (2015) 0.75

Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis. Int J Mol Sci (2017) 0.75

Systemic treatment of hepatocellular carcinoma: Past, present and future. World J Hepatol (2017) 0.75

Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016. J Transl Med (2017) 0.75

Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy. Diseases (2015) 0.75

Immunotherapy in Gastrointestinal Cancers. Biomed Res Int (2017) 0.75

Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives. J Clin Transl Hepatol (2017) 0.75

Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8(+) T Cell Responses to Chronic Viral Infections and Cancer. Front Immunol (2017) 0.75

Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to loco-regional therapies. Cancer Sci (2017) 0.75

A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. Diseases (2015) 0.75

Articles by these authors

Multiple links between transcription and splicing. RNA (2004) 4.90

DNA damage regulates alternative splicing through inhibition of RNA polymerase II elongation. Cell (2009) 3.66

Control of alternative splicing through siRNA-mediated transcriptional gene silencing. Nat Struct Mol Biol (2009) 3.47

Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology (2011) 3.26

Radioembolization for hepatocellular carcinoma. J Hepatol (2011) 2.97

Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general risk locus for autoimmune diseases. Am J Hum Genet (2007) 2.89

Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst (2006) 2.69

The transcriptional cycle of HIV-1 in real-time and live cells. J Cell Biol (2007) 2.69

IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci U S A (2006) 2.67

A combinatorial approach to create artificial homing endonucleases cleaving chosen sequences. Nucleic Acids Res (2006) 2.38

Molecular basis of xeroderma pigmentosum group C DNA recognition by engineered meganucleases. Nature (2008) 2.37

Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol (2003) 2.35

Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32

Common and different genetic background for rheumatoid arthritis and coeliac disease. Hum Mol Genet (2009) 2.15

Efficient targeting of a SCID gene by an engineered single-chain homing endonuclease. Nucleic Acids Res (2009) 2.14

Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology (2013) 2.08

Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med (2011) 2.04

Engineering of large numbers of highly specific homing endonucleases that induce recombination on novel DNA targets. J Mol Biol (2005) 2.04

Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma. Arthritis Rheum (2004) 2.03

Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol (2010) 2.00

The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Cancer Discov (2012) 1.95

Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res (2008) 1.92

Direct effects of type I interferons on cells of the immune system. Clin Cancer Res (2011) 1.91

Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology (2008) 1.87

Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology (2005) 1.75

Increased expression of Fcgamma receptors II and III on macrophages of rheumatoid arthritis patients results in higher production of tumor necrosis factor alpha and matrix metalloproteinase. Arthritis Rheum (2003) 1.74

Therapy for Whipple's disease. J Antimicrob Chemother (2007) 1.72

Acute liver failure in Spain: analysis of 267 cases. Liver Transpl (2007) 1.71

The carboxy terminal domain of RNA polymerase II and alternative splicing. Trends Biochem Sci (2010) 1.67

Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance. Liver Transpl (2013) 1.66

CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol (2003) 1.61

Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer (2008) 1.56

Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis. Liver Transpl (2009) 1.55

Inhibiting expression of specific genes in mammalian cells with 5' end-mutated U1 small nuclear RNAs targeted to terminal exons of pre-mRNA. Proc Natl Acad Sci U S A (2003) 1.55

Risk factors of lung, head and neck, esophageal, and kidney and urinary tract carcinomas after liver transplantation: the effect of smoking withdrawal. Liver Transpl (2011) 1.54

Tackling teenage turmoil: primary care recognition and management of mental ill health during adolescence. Fam Pract (2002) 1.51

Dysregulation of interferon regulatory factors impairs the expression of immunostimulatory molecules in hepatitis C virus genotype 1-infected hepatocytes. Gut (2013) 1.50

Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis (2007) 1.46

Cardiotrophin-1 reduces ischemia/reperfusion injury during liver transplant. J Surg Res (2012) 1.45

Amphiregulin: an early trigger of liver regeneration in mice. Gastroenterology (2005) 1.44

Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells. Hepatology (2011) 1.44

Incidence and 12-month outcome of non-transient childhood conversion disorder in the U.K. and Ireland. Br J Psychiatry (2013) 1.43

Biliary secretion of S-nitrosoglutathione is involved in the hypercholeresis induced by ursodeoxycholic acid in the normal rat. Hepatology (2010) 1.41

Up-regulation of microRNA 506 leads to decreased Cl-/HCO3- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. Hepatology (2012) 1.38

The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection. J Virol (2009) 1.36

Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology (2007) 1.32

Effect of adenovirus-mediated RNA interference on endogenous microRNAs in a mouse model of multidrug resistance protein 2 gene silencing. J Virol (2006) 1.32

Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. J Clin Oncol (2013) 1.32

Association of variation in Fcgamma receptor 3B gene copy number with rheumatoid arthritis in Caucasian samples. Ann Rheum Dis (2010) 1.31

The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med (Maywood) (2009) 1.31

Linkage proof for PTPN22, a rheumatoid arthritis susceptibility gene and a human autoimmunity gene. Proc Natl Acad Sci U S A (2007) 1.29

Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. J Virol (2007) 1.29

Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol (2004) 1.25

SimB16: modeling induced immune system response against B16-melanoma. PLoS One (2011) 1.25

Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res (2008) 1.24

Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol (2005) 1.23

Hepatitis C virus envelope components alter localization of hepatocyte tight junction-associated proteins and promote occludin retention in the endoplasmic reticulum. Hepatology (2008) 1.23

Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res (2011) 1.23

IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur J Immunol (2008) 1.22

Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin Cancer Res (2011) 1.22

The Toll-like receptor 4 Asp299Gly functional variant is associated with decreased rheumatoid arthritis disease susceptibility but does not influence disease severity and/or outcome. Arthritis Rheum (2004) 1.22

Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology (2013) 1.21

Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. Cancer Res (2008) 1.21

The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis. Hepatology (2008) 1.20

Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J Virol (2002) 1.19

Novel role for amphiregulin in protection from liver injury. J Biol Chem (2005) 1.19

Validation study of existing gene expression signatures for anti-TNF treatment in patients with rheumatoid arthritis. PLoS One (2012) 1.19

Molecular basis of engineered meganuclease targeting of the endogenous human RAG1 locus. Nucleic Acids Res (2010) 1.19

Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol (2005) 1.18

Association of STAT4 with rheumatoid arthritis: a replication study in three European populations. Arthritis Rheum (2008) 1.18

Genetic basis for clinical response to CTLA-4 blockade. N Engl J Med (2015) 1.18

Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J Immunol (2010) 1.17

Spontaneous regression of hepatocellular carcinoma: a systematic review. Eur J Gastroenterol Hepatol (2009) 1.17

Association of interleukin-18 expression with enhanced levels of both interleukin-1beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum (2003) 1.17

Bicarbonate-rich choleresis induced by secretin in normal rat is taurocholate-dependent and involves AE2 anion exchanger. Hepatology (2006) 1.16

Homing endonucleases: from basics to therapeutic applications. Cell Mol Life Sci (2010) 1.16

Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis. Pharmacogenomics (2007) 1.16

Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl (2012) 1.16

Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunol Immunother (2010) 1.15

Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res (2006) 1.14

Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res (2006) 1.14

N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB. Proc Natl Acad Sci U S A (2012) 1.14

Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol (2004) 1.13